Intervacc AB
STO:IVACC
Relative Value
The Relative Value of one IVACC stock under the Base Case scenario is hidden SEK. Compared to the current market price of 0.872 SEK, Intervacc AB is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
IVACC Competitors Multiples
Intervacc AB Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
I
|
Intervacc AB
STO:IVACC
|
297.2m SEK | 14.1 | -4.7 | -1.9 | -1.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.5B USD | 6.7 | 170.6 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.1B USD | 5.1 | 26.3 | 18.8 | 18.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.2 | 22.2 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD | 10.1 | 32.2 | 23.7 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD | 5.6 | 17.8 | 15 | 17.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.7B AUD | 3.9 | 20.3 | 13.6 | 16.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR | 14.6 | 34.4 | 58.8 | 60.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |